http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Novocure to Report First Quarter 2019 Financial Results
-
Novocure (NVCR) Commences Phase 3 Pivotal Trial in Recurrent Ovarian Cancer
-
Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer
-
Novocure Announces 48 Presentations and a Symposium Session on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2019
-
Novocure’s Chief Science Officer Retires after 17 Years of Service
-
Novocure to Participate in Oppenheimer’s 29th Annual Healthcare Conference
-
Novocure Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update
-
Novocure (NVCR) Announces Q4 Operating Statistics, Preliminary Net Revenues
-
Novocure Announces Fourth Quarter and Full Year 2018 Operating Statistics, Preliminary Net Revenues and Provides Company Update
-
Novocure to Participate in the 37th Annual J.P. Morgan Healthcare Conference
-
Novocure and the AACR Announce Four Inaugural Research Grants to Promote and Support Innovative Research on Tumor Treating Fields
-
Novocure (NVCR) Says Sub-Group Analysis of EF-14 Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Published in Journal of Neuro-Oncology
-
Sub-Group Analysis of Novocure’s EF-14 Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Published in Journal of Neuro-Oncology Demonstrating More Time on Optune® Predicted Increased Survival
-
Zai Lab and Novocure Awarded Deal of the Year
-
Novocure and Zai Lab Awarded Deal of the Year at 5th Annual BioCentury China Healthcare Summit in Shanghai, China
-
Zai Lab and Novocure Awarded Deal of the Year
-
Novocure Announces More than 70 Presentations on Tumor Treating Fields at 23rd Annual Meeting of the Society for Neuro-Oncology
-
Novocure and Zai Lab to Host Investor Event
-
Novocure Reports Third Quarter 2018 Financial Results and Provides Company Update
-
Novocure (NVCR) Announces Retirement of Founder Yoram Palti, MD, PhD and Louis J. Lavigne, Jr. from Board
-
Novocure Founder Professor Yoram Palti and Director Louis J. Lavigne, Jr. Retire from Board of Directors
-
Higher Delivered Dose of Tumor Treating Fields to Tumor Bed Associated with Improved Overall Survival in Newly Diagnosed Glioblastoma
-
Novocure (NVCR) Reports Results of PANOVA Phase 2 Pilot Trial in Advanced Pancreatic Cancer Suggesting Improved Survival of Patients Treated with Tumor Treating Fields
-
Pancreatology Publishes Results of the PANOVA Phase 2 Pilot Trial in Advanced Pancreatic Cancer Suggesting Improved Survival of Patients Treated with Tumor Treating Fields
-
Novocure (NVCR) Says Medicare DME MACs Have Accepted Local Coverage Determination Reconsideration Request for Optune
-
Novocure Announces that the Medicare DME MACs Have Accepted the Local Coverage Determination Reconsideration Request for Optune®
-
Novocure Announces 55 Presentations at European Association of Neuro-Oncology Meeting 2018
-
Novocure to Report Third Quarter 2018 Financial Results
-
Data from STELLAR Registration Trial of Tumor Treating Fields in Mesothelioma to be Presented at the IASLC 19th World Conference on Lung Cancer
-
Novocure (NVCR), Zai Lab (ZLAB) Announce Strategic Collaboration with License Agreement for Tumor Treating Fields in Greater China
-
Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China
-
Novocure (NVCR) Reports Final Results from STELLAR Phase 2 Registration Trial in Mesothelioma, Demonstrating 'Significant Extension in Median Overall Survival'
-
Tumor Treating Fields Plus Standard of Care Chemotherapy Significantly Extends Median Overall Survival by 6.1 Months in STELLAR Phase 2 Registration Trial in Mesothelioma Compared to Historical Contro
-
Novocure (NVCR), US Oncology Research Announce Collaboration on PANOVA-3 Trial
-
Novocure and US Oncology Research Announce Collaboration on PANOVA-3 Trial for Patients with Advanced Pancreatic Cancer
-
Novocure to Present at Two Upcoming Investor Conferences
-
Novocure (NVCR) Names Jeryl Hilleman to Board
-
Novocure Announces Addition to Its Board of Directors
-
Novocure (NVCR) Says Gynecologic Oncology Published Results of INNOVATE Phase 2 Pilot Study
-
Gynecologic Oncology Publishes Results of the INNOVATE Phase 2 Pilot Study Demonstrating Combination of Tumor Treating Fields with Paclitaxel May Improve Survival of Patients with Recurrent Ovarian Ca
-
Novocure Reports Second Quarter 2018 Financial Results and Provides Company Update
-
Novocure Announces 13 Presentations at American Society for Radiation Oncology 2018 Annual Meeting
-
Scientific Track Dedicated to Tumor Treating Fields at 40th International Conference of the IEEE Engineering in Medicine and Biology Society
-
Novocure Appoints Pritesh Shah as Chief Commercial Officer
-
Novocure to Report Second Quarter 2018 Financial Results
-
Novocure (NVCR) to Present INNOVATE-3 Phase 3 Pivotal Trial Design in Recurrent Ovarian Cancer at ASCO
-
Novocure to Present INNOVATE-3 Phase 3 Pivotal Trial Design in Recurrent Ovarian Cancer at the American Society of Clinical Oncology Annual Meeting 2018
-
Novocure Announces Changes to Its Board of Directors
-
Novocure Reports First Quarter 2018 Financial Results and Provides Company Update
-
Novocure (NVCR) Announces Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma

